Kimberly Rieger | Cancer Cell Biology | Innovative Research Award

Published on by Oncology

Innovative Research Award

Kimberly Rieger
Lahey Clinic, United States

              Kimberly Rieger
Affiliation Lahey Clinic
Country United States
Scopus ID 6602699362
Documents 87
Citations 15,323
h-index 33
Subject Area Cancer Cell Biology
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0002-8425

Kimberly Rieger is a cancer researcher associated with Lahey Clinic and the Cell and Molecular Biology research environment at Lahey Hospital & Medical Center. Her published work spans molecular oncology, cancer biology, microRNA regulation, tumor progression, biomarkers, and mechanisms associated with treatment response. [1]

Abstract

The Innovative Research Award profile recognizes Kimberly Rieger-Christ in the context of cancer cell biology and translational oncology research. Her research record includes studies examining molecular regulators of tumor behavior, microRNA-associated pathways, cancer biomarkers, metastatic phenotypes, and mechanisms influencing treatment response. [3] Such research contributes to understanding how molecular alterations can influence cancer progression and clinical outcomes.

Keywords

Cancer Cell Biology; Cancer Research; Molecular Oncology; MicroRNA; Bladder Cancer; Renal Cell Carcinoma; Lung Cancer; Biomarkers; Tumor Progression; Metastasis; Treatment Resistance; Translational Research; Molecular Diagnostics; Oncology.

Introduction

Cancer cell biology investigates the molecular and cellular processes that regulate malignant transformation, proliferation, invasion, metastasis, and response to therapy. Within this field, microRNAs and other regulatory molecules are important because they can influence multiple genes and signaling pathways simultaneously. Rieger-Christ’s published research has addressed these mechanisms across several cancer contexts, particularly urologic malignancies. [5]

Research Profile

The available research record places Rieger-Christ within a multidisciplinary cancer research environment involving molecular biology, genetics, gene expression, cell signaling, and cancer genomics. Her work has included experimental and translational studies addressing bladder cancer, renal cell carcinoma, prostate cancer, and lung cancer.Institutional sources describe research interests that include the molecular basis of genitourinary cancers and the development of improved approaches for diagnosis, prevention, and treatment. [2]

Research Contributions

A recurring contribution in the research record is investigation of microRNA biology in cancer. Published work has examined microRNA profiles associated with gemcitabine resistance in bladder carcinoma cell lines and microRNA signatures associated with invasive disease. [3] These studies address mechanisms that may help explain differences in tumor behavior and therapeutic response.

Publications

Selected publications associated with Kimberly Rieger-Christ demonstrate a sustained focus on molecular oncology. Her work includes studies of microRNA-mediated regulation, cancer invasion, treatment resistance, and molecular characteristics of tumor progression. The Lahey research publication archive records multiple contributions across these areas and provides DOI information for several publications. [3]

  • Kozinn et al. (2013), “MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines.”
  • Das et al. (2023), “The Roles of MiRNAs in Predicting Bladder Cancer Recurrence and Resistance to Treatment.”
  • Kalantzakos et al. (2023), “MicroRNA-155-5p Targets JADE-1, Promoting Proliferation, Migration, and Invasion in Clear Cell Renal Cell Carcinoma Cells.”

Research Impact

Research impact in cancer biology can be assessed through publication continuity, citation activity, methodological relevance, and contribution to clinically meaningful scientific questions. The supplied profile records 87 documents, 15,323 citations, and an h-index of 33. These figures are presented as the profile information supplied for this recognition page and may change as bibliographic databases are updated.The scientific relevance of the work is also reflected in its connection to cancer recurrence, treatment resistance, invasion, metastasis, and biomarker development. . [2]

Award Suitability

The Innovative Research Award is presented here as a recognition framework aligned with research activity in oncology and cancer cell biology. Rieger-Christ’s documented work in molecular cancer mechanisms, microRNA regulation, tumor progression, and translational research provides subject-matter relevance to an international research awards program focused on oncology and cancer research.Award suitability should ultimately be determined through the applicable nomination criteria, supporting evidence, peer or committee assessment, and verification of bibliographic information[2].

Conclusion

Kimberly Rieger-Christ’s research profile reflects sustained engagement with cancer cell biology and molecular oncology, with particular emphasis on microRNA regulation, tumor progression, metastatic phenotypes, treatment resistance, and biomarkers. Her publication record includes research addressing several clinically significant cancer types and molecular mechanisms.Within the context of the International Research Awards on Oncology and Cancer Research, these areas provide a reasonable scholarly basis for consideration under an Innovative Research Award category. The profile should be interpreted alongside current bibliographic records, institutional information, and the formal award evaluation process [3].

References

  1. ResearchGate. (n.d.). Kimberly Rieger-Christ research profile. ResearchGate.
    https://www.researchgate.net/profile/Kimberly-Rieger-Christ
  2. Lahey Hospital & Medical Center. (n.d.). Research: Ian C. Summerhayes Cell and Molecular Biology Laboratory.
    https://research.lahey.org/icsmb/research
  3. Lahey Hospital & Medical Center. (n.d.). Publications of the Ian C. Summerhayes Cell and Molecular Biology Laboratory.
    https://research.lahey.org/icsmb/publications?page=1
  4. Rieger-Christ, K. M., et al. (2015). A non-invasive miRNA based assay to detect bladder cancer in cell-free urine. Asian Journal of Translational Medicine Research.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC4697726/
  5. Elsevier. (n.d.). Scopus author details: Kimberly Rieger-Christ, Author ID 6602699362. Scopus.
    https://www.scopus.com/pages/authors/6602699362

Carlo Croce | Cancer Science | Innovative Research Award

Published on by Oncology

Innovative Research Award

Carlo Croce
Ohio State University, United States

                  Carlo Croce
Affiliation Ohio State University
Country United States
Scopus ID 7202975031
Documents 1,366
Citations 209,103
h-index 213
Subject Area Cancer Science
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0003-3788-1457

Carlo Croce is a cancer researcher affiliated with The Ohio State University whose research profile is centered on cancer biology, human cancer genetics and molecular mechanisms associated with malignancy. His institutional profile identifies cancer biology as an area of expertise and highlights human cancer genetics and microRNA research as major interests. [1] Bibliographic databases likewise identify his Ohio State affiliation and extensive publication record. [2]

Abstract

The Innovative Research Award recognition profile examines Carlo Croce in relation to contemporary cancer science and molecular oncology. Available institutional and bibliographic records associate his work with cancer biology, human cancer genetics and microRNA-related mechanisms. [1] His documented research activity includes a substantial body of peer-reviewed scientific literature addressing oncogenes, non-coding RNAs and cancer development. [3]

Keywords

Carlo Croce, Innovative Research Award, cancer science, cancer biology, oncology, human cancer genetics, microRNA, oncogenes, molecular oncology, Ohio State University.

Introduction

Cancer research increasingly integrates molecular genetics, cellular biology and translational science to understand how malignant transformation begins and progresses. Croce’s research has addressed molecular alterations associated with cancer, including oncogenes and regulatory mechanisms involving microRNAs. His published review on oncogenes discussed how molecular targets can contribute to the development of targeted anticancer strategies. [3]

Research Profile

The research profile is primarily situated within cancer biology and genetics. The Ohio State University profile identifies Cancer Biology & Genetics as an academic area and specifically lists human cancer genetics and the role of microRNAs in cancer among areas of expertise. [1] Bibliographic records further associate the researcher with a broad body of cancer-related publications and collaborations. [2]

Research Contributions

A significant theme of Croce’s research concerns the relationship between genetic alterations and malignant disease. His work on oncogenes has considered how genes involved in tumor initiation and progression can become relevant therapeutic targets. [3] His research has also examined microRNAs and their regulatory functions, contributing to broader investigation of non-coding RNA biology in cancer. [4]Research involving small non-coding RNAs has extended this molecular perspective into leukemia and related malignancies. A co-authored review published in Cancers examined small non-coding RNAs in leukemia and identified their relevance to cancer biology and potential therapeutic research. [5] These themes demonstrate the integration of molecular genetics with disease-focused oncology research.

Publications

Available scholarly records show an extensive publication history spanning cancer genetics, oncogenes, microRNAs and related molecular oncology topics. The Ohio State research portal lists more than one thousand research outputs associated with the researcher, while the current bibliographic author record identifies a similarly extensive body of indexed work. [2]

  • Oncogenes and cancer, New England Journal of Medicine, 2008.
  • Causes and consequences of microRNA dysregulation in cancer, Nature Reviews Genetics, 2009.
  • Small Non-Coding RNAs in Leukemia, Cancers, 2022. [5]

Research Impact

The supplied research metrics indicate a substantial bibliometric footprint, including 1,366 documents, 209,103 citations and an h-index of 213. Bibliographic information available through the author’s indexed profile confirms a very high level of publication and citation activity, although such metrics can change as databases are updated.Beyond quantitative indicators, the research record reflects sustained engagement with fundamental questions in cancer biology. Publications addressing oncogenes and microRNA regulation have helped frame molecular mechanisms as important components of modern cancer research and therapeutic investigation.

Award Suitability

Based on the supplied profile information, Carlo Croce demonstrates characteristics relevant to an Innovative Research Award in oncology and cancer research. The combination of a long-standing cancer research program, extensive scholarly output, substantial citation activity and research focused on molecular mechanisms provides a strong evidence base for consideration. [1] Final award decisions should remain subject to the event’s formal eligibility criteria and independent review.

Conclusion

Carlo Croce’s academic profile is closely associated with cancer biology, molecular genetics and oncology research. Institutional and bibliographic sources document extensive research activity and a substantial scholarly impact, while representative publications demonstrate sustained work on oncogenes, microRNAs and cancer-related molecular mechanisms. [2] On the basis of the supplied metrics and documented research themes, the profile is relevant to recognition under an innovative cancer research award.

References

  1. The Ohio State University. (n.d.). Carlo Croce — Molecular, Cellular and Developmental Biology Program. Ohio State University.
    https://mcdb.osu.edu/people/croce.5
  2. Elsevier. (n.d.). Carlo Maria Croce — Scopus author details, Author ID 7202975031. ScienceDirect.
    https://www.sciencedirect.com/author/7202975031/carlo-maria-croce
  3. Croce, C. M. (2008). Oncogenes and cancer. New England Journal of Medicine, 358(5), 502–511.
    https://doi.org/10.1056/NEJMra072367
  4. Croce, C. M. (2009). Causes and consequences of microRNA dysregulation in cancer. Nature Reviews Genetics, 10, 704–714.  https://doi.org/10.1038/nrg2634
  5. Balatti, V., & Croce, C. M. (2022). Small Non-Coding RNAs in Leukemia. Cancers, 14(3), 509.
    https://doi.org/10.3390/cancers14030509

Nour Abu Jayab | Cancer Cell Biology | Innovative Research Award

Published on by Oncology

Innovative Research Award

Nour Abu Jayab
University of Sharjah

                 Nour Abu Jayab
Affiliation University of Sharjah
Country United Arab Emirates
Scopus ID 58147288600
Documents 5
Citations 110
h-index 4
Subject Area Cancer Cell Biology
Event International Research Awards on Oncology and Cancer Research

Nour Abu Jayab is a researcher affiliated with the University of Sharjah whose scholarly activities contribute to the advancement of cancer cell biology and related biomedical investigations. Her publication record, citation performance, and research visibility demonstrate active engagement in contemporary oncology research. The Innovative Research Award recognizes scientific contributions that support the understanding of cancer mechanisms, translational biology, and evidence-based innovation within oncology and cancer research disciplines.[1][2]

Abstract

Nour Abu Jayab has established a developing research profile within cancer cell biology through contributions focused on understanding cellular mechanisms associated with cancer progression and therapeutic response. Her scholarly output demonstrates engagement with contemporary oncology challenges, including translational research and biomedical innovation. With a documented publication record and measurable citation impact, her work has contributed to scientific discussions within oncology-related disciplines. The combination of research productivity, interdisciplinary collaboration, and influence reflected through citation metrics supports recognition for innovative scientific achievement within the framework of the International Research Awards on Oncology and Cancer Research.[1][2]

Keywords

Cancer Cell Biology, Oncology Research, Translational Medicine, Cancer Mechanisms, Biomedical Research, Cellular Signaling, Tumor Biology, Scientific Innovation, Cancer Therapeutics, Research Impact

Introduction

Cancer research continues to rely on innovative investigations that improve understanding of cellular behavior, disease progression, and treatment response. Nour Abu Jayab contributes to this field through scholarly activities focused on cancer cell biology, supporting scientific knowledge relevant to modern oncology and translational biomedical research.[1]

Research Profile

Affiliated with the University of Sharjah, Nour Abu Jayab has developed a research portfolio within oncology-related disciplines. Her Scopus-indexed publications, citation performance, and measurable h-index indicate growing academic visibility and engagement with topics connected to cancer biology and biomedical sciences.[1][2]

Research Contributions

Her research contributions support understanding of biological processes relevant to cancer development and treatment. Through peer-reviewed publications, she has participated in advancing scientific evidence, encouraging interdisciplinary collaboration, and contributing to the broader knowledge base that informs future oncology investigations.[1][3]

Publications

The researcher maintains a Scopus-indexed publication record consisting of five documented scholarly works. These publications collectively address themes associated with cancer biology and biomedical research, contributing to scientific communication and supporting evidence-based advancement within oncology-related fields.[1]

Research Impact

With more than one hundred citations and an established h-index, Nour Abu Jayab’s research demonstrates measurable scholarly influence. Citation activity indicates that her publications have been referenced by other researchers, reflecting relevance and contribution to ongoing discussions within cancer and biomedical sciences.[1][2]

Award Suitability

The Innovative Research Award recognizes originality, scientific contribution, and research influence. Based on documented publication metrics, citation performance, and engagement in cancer cell biology, Nour Abu Jayab demonstrates characteristics aligned with award criteria emphasizing innovation, academic excellence, and contributions to oncology research.[1]

Conclusion

Nour Abu Jayab’s scholarly profile reflects active participation in cancer cell biology research. Her publication record, citation impact, and contribution to oncology-related knowledge support recognition within international research award programs that value innovation, scientific rigor, and meaningful advancement of biomedical science.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Nour Abu Jayab, Author ID 58147288600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=58147288600
  2. Abu Jayab, N., Abed, A., Talaat, I. M., & Hamoudi, R. (Year). The molecular mechanism of NF-κB dysregulation across different subtypes of renal cell carcinoma.https://pmc.ncbi.nlm.nih.gov/articles/PMC12147641/
  3. ResearchGate. (n.d.). Nour Abu Jayab Research Profile and Publications.https://www.researchgate.net/profile/Nour-Abu-Jayab

Assist Prof Dr. Juan Yakisich – Cancer Cell Biology – Best Researcher Award

Published on by Oncology

Assist Prof Dr. Juan Yakisich - Cancer Cell Biology - Best Researcher Award

Hampton University - United States

AUTHOR PROFILE

Google Scholar

Orcid

EARLY ACADEMIC PURSUITS

Juan Sebastian Yakisich, MD, PhD, pursued an interdisciplinary biomedical research path, obtaining his doctoral education at the esteemed Karolinska Institute in Europe, one of the largest and most prestigious medical universities. His early academic pursuits laid the foundation for his expertise in cell & molecular biology, cancer biology & molecular oncology, and pharmacology.

PROFESSIONAL ENDEAVORS

Following his doctoral education, Dr. Yakisich undertook postdoctoral training at the Department of Molecular and Cellular Medicine, Texas A&M University, College Station, TX. His professional journey also included a highly competitive and prestigious research grant from the Swedish Research Council, leading to four additional years as a project leader at the Department of Clinical Neuroscience, Karolinska Institute.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER CELL BIOLOGY

Dr. Yakisich possesses a comprehensive background in cancer cell biology and pharmacology, specializing in cellular and molecular biology, anticancer drug screening, and cancer stem cell biology. His significant contributions include the development of a groundbreaking cancer stem cell model (The stemness phenotype model) applicable to various cancer types, with substantial clinical implications. Additionally, he pioneered effective strategies for anticancer drug screening, addressing limitations in existing programs.

IMPACT AND INFLUENCE

As an oncology researcher, Dr. Yakisich has made a substantial impact, contributing to the understanding and treatment of various cancers, including brain tumors, cervical, lung, and breast cancers. His work has not only shaped research directions but has practical applications in clinical settings, improving the screening of oncology markers and enhancing drug delivery into cancer cells.

ACADEMIC CITES

Dr. Yakisich's academic achievements are reflected in his publication record, including over 60 peer-reviewed original articles and reviews in international leading journals. He has served as a grant and postdoctoral fellowship reviewer for NASA and held editorial and associate board memberships in international peer-reviewed journals such as Frontiers in Pharmacology.

LEGACY AND FUTURE CONTRIBUTIONS HIGHLIGHT

In his tenure at Hampton University, Dr. Yakisich has continued to contribute significantly, publishing over twenty-five peer-reviewed articles and three book chapters. His commitment to education is evident through mentoring and training Master's, PhD, undergraduate, and high school students in multiple countries. Dr. Yakisich emphasizes a commitment to mentor and train underrepresented minorities in basic and translational research, leaving a lasting legacy of diversity and inclusion.

FUTURE CONTRIBUTIONS

Looking ahead, Dr. Yakisich is actively engaged in the development of aptamer-based biomedical tools for identifying oncology markers, pathogen detection and elimination, and drug delivery into cancer cells. His dedication to mentoring and training underscores a commitment to advancing scientific knowledge and fostering the next generation of researchers, ensuring a continued impact on the field of biomedical research.

NOTABLE PUBLICATIONS

A short post reattachment ultra-sensitive window of time in human cancer cells as therapeutic target of prolonged low dose administration of specific compounds. 2024

Two-Step Preparation of Protein-Decorated Biohybrid Quantum Dot Nanoparticles for Cellular Uptake. 2023

Phenotypic Characterization of 2D and 3D Prostate Cancer Cell Systems Using Electrical Impedance Spectroscopy. 2023

Downregulation of DKK-1 and Upregulation of B - Catenin in Cancer Floating Spheroids is Associated with Chemoresistance to Wnt Signaling Pathway Inhibitors. 2022

Translational Gap in Lung Cancer Research. 2022